Dimorphism of the prodrug l‐tyrosine ethyl ester: Pressure–temperature state diagram and crystal structure of phase II
Polymorphism is important in the field of solid‐state behavior of drug molecules because of the continuous drive for complete control over drug properties. By comparing different structures of a series of l‐tyrosine alkyl esters, it became apparent that the ethyl ester possesses dimorphism. Its stru...
Saved in:
Published in | Journal of pharmaceutical sciences Vol. 100; no. 11; pp. 4774 - 4782 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Elsevier Inc
01.11.2011
Wiley Subscription Services, Inc., A Wiley Company Wiley American Pharmaceutical Association Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Polymorphism is important in the field of solid‐state behavior of drug molecules because of the continuous drive for complete control over drug properties. By comparing different structures of a series of l‐tyrosine alkyl esters, it became apparent that the ethyl ester possesses dimorphism. Its structure was determined by powder diffraction and verified by density functional theory calculations; it is orthorhombic, P212121 with a = 12.8679(8) Å, b = 14.7345(7) Å, c = 5.8333 (4) Å, V = 1106.01(11) Å, and Z = 4. The density of phase II is in line with other tyrosine alkyl esters and its conformation is similar to that of l‐tyrosine methyl ester. The hydrogen bonds exhibit similar geometries for phase I and phase II, but the H‐bonds in phase I are stronger. The solid II–solid I transition temperature is heating‐rate dependent; it levels off at heating rates below 0.5 K min–1, leading to a transition temperature of 306 ± 4 K. Application of the Clapeyron equation in combination with calorimetric and X‐ray data has led to a topological diagram providing the relative stabilities of the two solid phases as a function of pressure and temperature; phase II is stable under ambient conditions. © 2011 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:4774–4782, 2011 |
---|---|
Bibliography: | istex:A6CB95B66AEFE3A497646097528747267DE28D49 ArticleID:JPS22672 ark:/67375/WNG-K8VKHQS0-D ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0022-3549 1520-6017 |
DOI: | 10.1002/jps.22672 |